<DOC>
	<DOCNO>NCT03081936</DOCNO>
	<brief_summary>This pilot study primarily aim compare effect breast feeding , A1 versus A2Â®cow milk base formula alimentation gastrointestinal digestion . The impact study product fecal myeloperoxidase ( MPO ) , short-chain fatty acid ( SCFA ) , secretory immunoglobulin A ( sIgA ) concentration , gastrointestinal tolerance , defecate habit infant growth also evaluate .</brief_summary>
	<brief_title>Comparative A1 v A2 Formula Breast Feeding Alimentation Gastrointestinal Digestion Infant</brief_title>
	<detailed_description />
	<criteria>Willing formula feeding consume 600ml IF day ; Have normal electrocardiogram ( ECG ) blood pressure quiet respiration . Agree take medication , supplement , nutrition dairy product include acidophilus milk ; Parent ( ) legal guardian 's consent study willing comply study procedure ; Parent ( ) guardian infant agree enroll infant another clinical study participate study ; Fully understand nature , objective , benefit potential risk side effect study . Twins , multiple birth , low birth weight child , birth weight child early birth child gestational age le 37 week ; During pregnancy , mother pregnancy complication disease may affect result ; Having serious disease may affect study intervention , neonatal sepsis , pneumonia ( associate respiratory failure ) , heart failure disease ; Having neonatal diarrhea acute respiratory infection within 48hours enrollment ; Having potential metabolic disease , chronic disease , congenital malformation , central nervous system disorder , neuromuscular disorder diseases affect bone metabolism may affect growth study result ; Having take food contain prebiotics probiotic tithe 15 day enrollment ; Body weighttoheight Zvalue &lt; 3 accord standard World Health Organization ( WHO ) ; Receiving hormone therapy intravenous nutrition ; Lactose intolerance allergic ingredient study product ; Have history faecal impaction ; Have participate similar dairy probioticscontaining product 's clinical trial within 3 month screen ; Currently take medicine cardiovascular metabolic disease ; Currently suffer gastrointestinal disorder gastrointestinal disease , include limited : irritable bowel syndrome , colitis , ulcerative colitis , celiac disease , irritable bowel syndrome ( IBS ) ; Had hospitalization within 3 month screen ; According investigator 's judgment , current frequent user drug may affect gastrointestinal function immune system ; Unable comply study schedule .</criteria>
	<gender>All</gender>
	<minimum_age>40 Days</minimum_age>
	<maximum_age>60 Days</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>